NCT03065387View on ClinicalTrials.gov

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

October 31, 2017

Primary Completion Date

October 1, 2025

Study Completion Date

October 1, 2025

Conditions
Advanced Malignant Solid NeoplasmEGFR Gene AmplificationEGFR Gene MutationERBB2 Gene AmplificationERBB2 Gene MutationERBB3 Gene MutationERBB4 Gene MutationKRAS Gene MutationMetastatic Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm
Interventions
DRUG

Everolimus

Given PO

DRUG

Neratinib

Given PO

DRUG

Palbociclib

Given PO

DRUG

Trametinib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER